Exagamglogene Autotemcel PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Autologous CD34+ cells are edited ex vivo at the erythroid-specific enhancer of BCL11A, reducing BCL11A expression in erythroid cells and increasing fetal haemoglobin (HbF) production after engraftment.
Indications / reported uses
Treatment of sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises, under the product-specific eligibility criteria
Treatment of transfusion-dependent beta-thalassaemia in patients aged 12 years and older under the applicable US and EU product authorisations
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Exagamglogene Autotemcel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Exagamglogene Autotemcel Permitted Daily Exposure (PDE) report (the Exagamglogene Autotemcel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Exagamglogene Autotemcel Occupational Exposure Limit (OEL) report (the Exagamglogene Autotemcel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.